Genprex stock plunges to 52-week low of $0.27

Genprex Inc. (NASDAQ:GNPX) shares have tumbled to $0.29, near its 52-week low of $0.28, as market headwinds continue to challenge the biotech sector. With a market capitalization of just $2.77 million, InvestingPro analysis suggests the stock is currently trading below its Fair Value. The company, which specializes in gene therapy for cancer and other diseases, has seen its stock price severely retract over the past year, with a staggering decline of 88.52%. Notably, InvestingPro data shows the stock often moves independently of the market with a beta of -0.15. This sharp decline reflects investor concerns over the company’s pipeline progress and the broader market’s shifting sentiment towards risk-heavy biotech investments. As Genprex navigates through a critical phase of development and seeks to regain investor confidence, all eyes will be on their ability to deliver on clinical milestones and secure the necessary funding to advance their therapies. While the company maintains more cash than debt on its balance sheet, InvestingPro analysis reveals a weak Financial Health Score of 1.17, with analysts anticipating continued losses this year. Investors should note the company’s next earnings report is due on March 31, 2025.

In other recent news, Genprex, Inc. has made strides in their gene therapy programs, highlighting significant developments in both lung cancer and diabetes research. The company announced positive preclinical data for their lead drug candidate, Reqorsa® Gene Therapy, aimed at overcoming resistance in KRASG12C mutant non-small cell lung cancer. This data will be presented at the 2025 American Association for Cancer Research Annual Meeting, showcasing the potential of Reqorsa in combination with existing treatments. In the realm of diabetes, Genprex has entered a collaboration with a contract development and manufacturing organization to explore a non-viral delivery system for their diabetes gene therapy candidate. Additionally, Genprex has consolidated its licensing agreements with the University of Pittsburgh, granting exclusive global rights to several diabetes-related gene therapy technologies. The company has also established Convergen Biotech, Inc., a subsidiary to advance its diabetes program. Meanwhile, Genprex faces challenges with Nasdaq compliance, having received notifications regarding non-compliance with minimum bid price and stockholders’ equity requirements. The company is actively working to address these issues, with deadlines set for compliance later in 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.